Skyrizi (risankizumab ... industrial biotech, and digital medicine. AbbVie has joined the ranks of pharma groups trying to develop weight-loss drugs, licensing an amylin agonist from Gubra ...

AbbVie has built the case for its IL-23 inhibitor Skyrizi as a treatment for Crohn’s disease, saying its drug was more effective than Johnson & Johnson’s widely-used Stelara in a head-to-head ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting off on a very different note. According to iSpot.TV’s analysis of ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a promising investment despite key risks.

The decline was offset by sales of its newer arthritis drugs Skyrizi, which soared by 57% to $3.78 billion, and Rinvoq, which logged a 46% gain to $1.83 billion. Chief Executive Robert Michael ...